Search

everythinglearnresearchcommunity

for

Search:↓

A woman with alopecia universalis shares her positive experience of being bald, finding it freeing and less worrisome. She also discusses her skincare routine using Korean products.

The user had lab work done to check for thyroid issues and other factors related to hair loss. They are seeking advice on which lab results are important for understanding hair loss and what the optimal levels should be.

The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation is about analyzing receded temple closeups for signs of fibrosis, scarring, or androgenetic alopecia (AGA). Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned in the conversation.

Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.

Oral Minoxidil can cause puffy eyes and fluid retention. Adding an ACE inhibitor or ARB, like Telmisartan, may help mitigate these side effects.

The conversation discusses sourcing pure latanoprost from the gray market for research and making a homemade solution. Concerns about potential dangers and experiences with this method are raised.

Why androgenic alopecia affects the scalp rather than other body parts, potential explanations for this phenomenon, treatments available to combat hair loss, and the implications of male attractiveness in modern society.

The conversation discusses hair transplants, including the use of techniques like FUE and the importance of a good donor area to avoid visible bald patches. It also touches on alternative treatments like Minoxidil, Finasteride, and Pyrolutimide, and debates the idea of embracing baldness versus seeking treatments.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.